Board of Directors
Our Board of Directors has a wide range of expertise, from drug development to business management. We bring sharp commercial focus and world-class science together to advance promising therapies.
Solid Biosciences has assembled a world-class team of experts comprised of leading immunologists, molecular biologists, clinicians and gene therapy researchers. Together, these field-leading authorities are helping Solid progress our candidates into the clinic.
Solid is the English translation of Eytani, the Hebrew name of Ilan and Annie Ganot’s son, who was diagnosed with Duchenne muscular dystrophy in 2012.
Following this diagnosis, Ilan and Annie co-founded Solid Biosciences with our Chairman of the Board, Andrey Zarur, Matt Arnold and Gilad Hayeem, who were all unsatisfied with the existing Duchenne treatment landscape. Together, they built a disease-focused company with the team, infrastructure and potential to advance innovative science quickly and responsibly.